2nd Generation Microtox® PD equipment shipping

RNS Number : 7362P
Deepverge PLC
21 October 2021
 

21 October 2021

 

DeepVerge PLC

 

("DeepVerge" or "Company")

 

Second Generation Microtox® PD[i] pandemic response equipment shipping to UK, China and India

Modern Water, a division of DeepVerge (AIM: DVRG) announces £2.2m worth of new orders for newly enhanced monitoring equipment with upgraded software which are being shipped to the UK, India and China to meet customer and partner obligations for delivery in this financial year.

 

Initial shipments of Pandemic Response Equipment

The shipments include upgraded Microtox® toxicity monitoring, new models of the Microtox® PD range for SARS-CoV-2 and other pathogen monitoring as well as Microsaic mass spectrometer equipment to monitor forever chemicals and contaminants of emerging concern.

 

New software, data management capability, dashboards, encryption, and new AI models are fully integrated as part of the shipped solutions that offer three levels of surveillance:

 

1.  Traditional pollution - toxicity and heavy metals

2.  Pandemic surveillance, and

3.   PFASs - "Forever Chemicals" (Per- and Polyfluoroalkyl Substances)

 

Gerry Brandon CEO of DeepVerge plc commented:

"Just 11 months following the Modern Water acquisition, DeepVerge is shipping 2nd generation real-time pandemic response equipment with SARS-CoV-2 detection fully integrated to meet initial customer demand after the successful demonstration of Phase III field trials announced in our RNS[ii] of 24 June 2021.

 

"The success of the DeepVerge new product division, based in York, UK and Cork, Ireland, is a credit to the teams working across the Group who have delivered more than could have been hoped for when we announced the data science, physics and epidemiology centre of excellence in the RNS[iii] of 6 May 2021.  As a result, we now have upgraded Microtox equipment with the capability to monitor COVID-19 in real-time and other pathogens as well as pollutants, being shipped across three continents."

 

DeepVerge New Product Development in Cork, Ireland

 

The equipment was assembled in DeepVerge's product development facility in Cork, Ireland which has been up and running for the past six months. The new generation of Modern Water surveillance solutions also come with enhanced data generation capability and AI learning that allows added value extrapolation of data being delivered in real-time.

 

This new facility gives DeepVerge control of final assembly and Quality Assurance as well as providing a world serving logistics centre that includes the EU, China, and India with delivery of the solutions to national and provincial government and state controlled utilities. It will play a vital part in the worldwide supply chain being developed with existing partners and develop new manufacturing partnerships in China.

 

While the software solution that is incorporated for this generation of equipment is packaged and COTS (commercial off the shelf), all data generated by customers and partners in-country equipment is encrypted to military grade standard and remains in-country in recognition that the customer or sovereign state owns the data, which is important with health data as it is increasingly regarded as a national bio security matter.

 

 

 

Enquiries:

 

DeepVerge plc

Gerry Brandon, CEO

+44 (0) 734 0055 648

 

 

 

 

SPARK Advisory Partners Limited

(Nominated Adviser)

Neil Baldwin

+44 (0) 113 370 8974

 

 

 

Turner Pope Investments (TPI) Limited

(Broker)

Andy Thacker/James Pope

+44 (0) 20 3657 0050

 

 

Market Abuse Regulation (MAR) Disclosure

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins. Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin microbiome for most of the top 20 global cosmetic company clients and remotely detect and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.

 

About Microsaic

Microsaic listed on AIM in 2011 to develop and commercialise micro-engineering chip-based mass spectrometry equipment. Having invested £30m over the last 20 years before and after the IPO, Microsaic has a robust patent portfolio in cutting-edge technology purpose built for "Industry 4.0" which enables analytical detection and characterisation at the point-of-need, whether within a human health environment, conventional laboratory setting, or within a bioprocessing facility for continuous mass spectrometer detection and monitoring of data at any step in the process workflow.

 

 

[i]Microtox® PD has been designed to be retrofitted into existing Modern Water equipment to detect and identify a range of infectious viruses and bacteria including SARS-CoV-2, E.coli, Legionella and Cryptosporidium, on a single chip, using AI, in real-time

 

[ii] https://www.londonstockexchange.com/news-article/DVRG/microtox-successful-phase-3-field-trials/15030475

 

[iii]https://www.londonstockexchange.com/news-article/DVRG/new-ai-centre-of-excellence-in-cork/14965354

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAPEEADEFFFA
UK 100

Latest directors dealings